department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

LISDEXAMFETAMINE DIMESYLATE · pharmadog

pharmadog
drugs
LISDEXAMFETAMINE DIMESYLATE

drug

patient view →

LISDEXAMFETAMINE DIMESYLATE

Marketedupdated 2mo ago

by Actavis Elizabeth LLC

Approved

community read0 votes

all catalysts(5)

approval · 5

LISDEXAMFETAMINE DIMESYLATE — FDA approval

LISDEXAMFETAMINE DIMESYLATE

LISDEXAMFETAMINE DIMESYLATE — FDA approval

LISDEXAMFETAMINE DIMESYLATE

ARYNTA (LISDEXAMFETAMINE DIMESYLATE) — FDA approval

LISDEXAMFETAMINE DIMESYLATE

ARYNTA (LISDEXAMFETAMINE DIMESYLATE) — FDA approval

LISDEXAMFETAMINE DIMESYLATE

LISDEXAMFETAMINE DIMESYLATE — FDA approval

LISDEXAMFETAMINE DIMESYLATE

News(0)

no news has mentioned this drug yet

brand

LISDEXAMFETAMINE DIMESYLATE

generic

LISDEXAMFETAMINE DIMESYLATE

indication

Attention Deficit Hyperactivity Disorder (ADHD)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 16, 2040

~13.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Aug 30, 2040formulationUS 11576878
Apr 16, 2040formulationUS 12433859
Apr 16, 2040formulationUS 12582620

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval112 co-mentions · 56 sources
drugARYNTA97 co-mentions · 74 sources
tagSmall Molecule56 co-mentions · 56 sources
companySun Pharmaceutical Industries Ltd31 co-mentions · 10 sources
tagRecall17 co-mentions · 10 sources
companyOhm Laboratories Inc15 co-mentions · 8 sources
tagDrug Shortage8 co-mentions · 8 sources
companyApotex Corp1 co-mentions · 1 sources

Trials studying LISDEXAMFETAMINE DIMESYLATE

phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorderrecruitingn=105
phase4Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndromecompletedn=26
phase1To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.completedn=48
phase4Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autismcompletedn=48